Drugs & Targets Kymriah granted FDA priority review and EMA filing acceptance October 29, 2021Vol.47 No.40
Drugs & Targets Morphogenesis receives FDA ‘fast track’ designation for skin cancer vaccine October 29, 2021Vol.47 No.40
Drugs & Targets Foundation Medicine now an in-network provider for Humana Military and Health Net Federal Services October 29, 2021Vol.47 No.40
Drugs & Targets Citius acquires license for late-phase III oncology immunotherapy for cutaneous T-cell lymphoma October 29, 2021Vol.47 No.40
Drugs & Targets Cardinal Health receives $750,000 FDA grant to study oncology trial designs by comparing RWE to RCT results October 29, 2021Vol.47 No.40
Drugs & Targets Keytruda + chemo gets EC approval for locally recurrent unresectable or metastatic triple-negative breast cancer October 22, 2021Vol.47 No.39
Drugs & Targets Opdivo + chemo gets EC approval for metastatic gastric cancer, GEJ cancer, or EAC October 22, 2021Vol.47 No.39
Drugs & Targets Point32Health, Takeda enter risk-sharing agreement for Alunbrig in ALK+NSCLC October 22, 2021Vol.47 No.39
Drugs & Targets FDA approval makes Tecentriq the first adjuvant treatment for NSCLC October 15, 2021Vol.47 No.38
